Dynavax Technologies (NASDAQ:DVAX) Hits New 1-Year Low Following Analyst Downgrade

Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday after JMP Securities lowered their price target on the stock from $33.00 to $31.00. JMP Securities currently has a market outperform rating on the stock. Dynavax Technologies traded as low as $9.62 and last traded at $9.72, with a volume of 6232072 shares changing hands. The stock had previously closed at $10.92.

A number of other equities analysts have also commented on DVAX. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday. The Goldman Sachs Group dropped their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of "Hold" and a consensus price target of $24.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Bryce Point Capital LLC acquired a new position in Dynavax Technologies in the first quarter worth $357,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Dynavax Technologies by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock valued at $401,000 after buying an additional 1,453 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Dynavax Technologies during the first quarter worth about $292,000. Choreo LLC boosted its stake in Dynavax Technologies by 3.2% in the first quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock valued at $452,000 after acquiring an additional 1,065 shares during the period. Finally, Moloney Securities Asset Management LLC acquired a new position in Dynavax Technologies in the first quarter valued at approximately $131,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Dynavax Technologies Price Performance

The company has a market capitalization of $1.19 billion, a P/E ratio of 54.00 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a fifty day moving average price of $12.41 and a 200 day moving average price of $12.57.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). The firm had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.